Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

Patterns of distant metastases in vulvar cancer.

Prieske K, Haeringer N, Grimm D, Trillsch F, Eulenburg C, Burandt E, Schmalfeldt B, Mahner S, Mueller V, Woelber L.

Gynecol Oncol. 2016 Sep;142(3):427-34. doi: 10.1016/j.ygyno.2016.07.009. Epub 2016 Jul 9.

PMID:
27401841
2.

The Risk of Contralateral Non-sentinel Metastasis in Patients with Primary Vulvar Cancer and Unilaterally Positive Sentinel Node.

Woelber L, Eulenburg C, Grimm D, Trillsch F, Bohlmann I, Burandt E, Dieckmann J, Klutmann S, Schmalfeldt B, Mahner S, Prieske K.

Ann Surg Oncol. 2016 Aug;23(8):2508-14. doi: 10.1245/s10434-016-5114-6. Epub 2016 Feb 8.

PMID:
26856721
3.

E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer.

Trillsch F, Kuerti S, Eulenburg C, Burandt E, Woelber L, Prieske K, Eylmann K, Oliveira-Ferrer L, Milde-Langosch K, Mahner S.

Br J Cancer. 2016 Jan 19;114(2):213-20. doi: 10.1038/bjc.2015.436.

PMID:
26757261
4.

Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer.

Mahner S, Woelber L, Mueller V, Witzel I, Prieske K, Grimm D, Keller-V Amsberg G, Trillsch F.

Front Oncol. 2015 Oct 5;5:211. doi: 10.3389/fonc.2015.00211. eCollection 2015. Review.

5.

The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.

Nassir M, Guan J, Luketina H, Siepmann T, Rohr I, Richter R, Castillo-Tong DC, Zeillinger R, Vergote I, Van Nieuwenhuysen E, Concin N, Marth C, Hall C, Mahner S, Woelber L, Sehouli J, Braicu EI.

Tumour Biol. 2016 Mar;37(3):3009-16. doi: 10.1007/s13277-015-4031-9. Epub 2015 Sep 29.

PMID:
26419591
6.

Sexual Activity and Function in Patients With Gynecological Malignancies After Completed Treatment.

Grimm D, Hasenburg A, Eulenburg C, Steinsiek L, Mayer S, Eltrop S, Prieske K, Trillsch F, Mahner S, Woelber L.

Int J Gynecol Cancer. 2015 Jul;25(6):1134-41. doi: 10.1097/IGC.0000000000000468.

PMID:
26098093
7.

Sexual activity and function after surgical treatment in patients with (pre)invasive vulvar lesions.

Grimm D, Eulenburg C, Brummer O, Schliedermann AK, Trillsch F, Prieske K, Gieseking F, Selka E, Mahner S, Woelber L.

Support Care Cancer. 2016 Jan;24(1):419-28. doi: 10.1007/s00520-015-2812-8. Epub 2015 Jun 23.

PMID:
26094599
8.

Utility of EFC quality indicators for colposcopy in daily practice: results from an independent, prospective multicenter trial.

Luyten A, Hagemann I, Scherbring S, Boehmer G, Gieseking F, Woelber L, Glasenapp F, Hampl M, Kuehler-Obbarius C, van den Bergh M, Leeson S, Redman C, Petry KU; Studiengruppe Kolposkopie eV (SGK) and G-CONE (German Colposcopy Network).

Eur J Obstet Gynecol Reprod Biol. 2015 Aug;191:43-7. doi: 10.1016/j.ejogrb.2015.05.020. Epub 2015 May 30.

PMID:
26071669
9.

Systemic treatment of vulvar cancer.

Mahner S, Prieske K, Grimm D, Trillsch F, Prieske S, von Amsberg G, Petersen C, Mueller V, Jaenicke F, Woelber L.

Expert Rev Anticancer Ther. 2015 Jun;15(6):629-37. doi: 10.1586/14737140.2015.1037837. Epub 2015 May 21. Review.

PMID:
25997120
10.

A systematic model specification procedure for an illness-death model without recovery.

Eulenburg C, Mahner S, Woelber L, Wegscheider K.

PLoS One. 2015 Apr 13;10(4):e0123489. doi: 10.1371/journal.pone.0123489. eCollection 2015.

11.

A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.

Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Chan IS, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A; Broad Spectrum HPV Vaccine Study.

N Engl J Med. 2015 Feb 19;372(8):711-23. doi: 10.1056/NEJMoa1405044.

12.

Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study.

Mahner S, Jueckstock J, Hilpert F, Neuser P, Harter P, de Gregorio N, Hasenburg A, Sehouli J, Habermann A, Hillemanns P, Fuerst S, Strauss HG, Baumann K, Thiel F, Mustea A, Meier W, du Bois A, Griebel LF, Woelber L; AGO-CaRE 1 investigators.

J Natl Cancer Inst. 2015 Jan 24;107(3). pii: dju426. doi: 10.1093/jnci/dju426. Print 2015 Mar.

13.

Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study.

Trillsch F, Mahner S, Vettorazzi E, Woelber L, Reuss A, Baumann K, Keyver-Paik MD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroeder W, Muenstedt K, Richter B, Fotopoulou C, Schmalfeldt B, Burges A, Ewald-Riegler N, de Gregorio N, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Kommoss S, Kommoss F, Hauptmann S, du Bois A.

Br J Cancer. 2015 Feb 17;112(4):660-6. doi: 10.1038/bjc.2014.648. Epub 2015 Jan 6.

14.

Utility and Reproducibility of the International Federation for Cervical Pathology and Colposcopy Classification of Transformation Zones in Daily Practice: A Multicenter Study of the German Colposcopy Network.

Luyten A, Buttmann-Schweiger N, Hagemann I, Scherbring S, Boehmer G, Gieseking F, Woelber L, Glasenapp F, Hampl M, Kuehler-Obbarius C, van den Bergh M, Petry KU; German Colposcopy Network (G-CONE) and the German Colposcopy Study Group.

J Low Genit Tract Dis. 2015 Jul;19(3):185-8. doi: 10.1097/LGT.0000000000000069.

PMID:
25089552
15.

Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study.

Trillsch F, Mahner S, Woelber L, Vettorazzi E, Reuss A, Ewald-Riegler N, de Gregorio N, Fotopoulou C, Schmalfeldt B, Burges A, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Baumann K, Keyver-Paik MD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroeder W, Muenstedt K, Richter B, Kommoss F, Hauptmann S, du Bois A.

Ann Oncol. 2014 Jul;25(7):1320-7. doi: 10.1093/annonc/mdu119. Epub 2014 Mar 11.

16.

Clinical management of epithelial ovarian cancer during pregnancy.

Grimm D, Woelber L, Trillsch F, Keller-v Amsberg G, Mahner S.

Eur J Cancer. 2014 Mar;50(5):963-71. doi: 10.1016/j.ejca.2013.12.020. Epub 2014 Jan 23. Review.

PMID:
24462638
17.

Carbonic anhydrase IX is strongly overexpressed in adenocarcinoma in situ of the cervix uteri.

Choschzick M, Woelber L, Gieseking F, Oosterwijk E, Tennstedt P.

Histopathology. 2014 Mar;64(4):600-2. doi: 10.1111/his.12288. Epub 2013 Nov 12. No abstract available.

PMID:
24111817
18.

Adjuvant therapy in node-positive vulvar cancer.

Mahner S, Trillsch F, Kock L, Rohsbach D, Petersen C, Kruell A, Harter P, Jaenicke F, Woelber L.

Expert Rev Anticancer Ther. 2013 Jul;13(7):839-44. doi: 10.1586/14737140.2013.811063. Review.

PMID:
23875662
19.

Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer.

Mathey S, Graeser MK, Zu Eulenburg C, Woelber L, Trillsch F, Jaenicke F, Müller V, Milde-Langosch K, Mahner S.

Oncology. 2013;85(2):69-77. doi: 10.1159/000351032. Epub 2013 Jul 16.

PMID:
23860180
20.

Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (BOT).

Trillsch F, Ruetzel JD, Herwig U, Doerste U, Woelber L, Grimm D, Choschzick M, Jaenicke F, Mahner S.

J Ovarian Res. 2013 Jul 9;6(1):48. doi: 10.1186/1757-2215-6-48.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk